ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating in a note issued to investors on Monday.
ANIP has been the topic of several other reports. Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an "outperform" rating and a $80.00 target price on the stock. Leerink Partnrs upgraded ANI Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday, December 11th. Finally, HC Wainwright reissued a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $79.00.
Check Out Our Latest Analysis on ANIP
ANI Pharmaceuticals Stock Down 0.7 %
Shares of ANIP traded down $0.43 during mid-day trading on Monday, hitting $60.62. 438,170 shares of the company's stock were exchanged, compared to its average volume of 225,686. The stock has a market cap of $1.27 billion, a price-to-earnings ratio of -110.22 and a beta of 0.74. The firm has a fifty day moving average of $57.64 and a two-hundred day moving average of $58.13. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals has a twelve month low of $52.50 and a twelve month high of $70.81.
Insider Activity at ANI Pharmaceuticals
In other news, CFO Stephen P. Carey sold 7,500 shares of the firm's stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the sale, the chief financial officer now owns 154,468 shares in the company, valued at approximately $8,617,769.72. This trade represents a 4.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the business's stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total transaction of $60,000.00. Following the transaction, the senior vice president now directly owns 49,059 shares in the company, valued at $2,943,540. This trade represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 10,300 shares of company stock worth $584,009 in the last 90 days. 12.70% of the stock is owned by company insiders.
Institutional Trading of ANI Pharmaceuticals
Hedge funds have recently bought and sold shares of the stock. Louisiana State Employees Retirement System raised its position in shares of ANI Pharmaceuticals by 3.9% during the third quarter. Louisiana State Employees Retirement System now owns 8,000 shares of the specialty pharmaceutical company's stock valued at $477,000 after buying an additional 300 shares during the last quarter. State of Alaska Department of Revenue increased its stake in ANI Pharmaceuticals by 5.2% during the third quarter. State of Alaska Department of Revenue now owns 9,467 shares of the specialty pharmaceutical company's stock valued at $564,000 after acquiring an additional 464 shares during the period. New York State Teachers Retirement System raised its holdings in ANI Pharmaceuticals by 1.7% in the 3rd quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company's stock valued at $1,439,000 after acquiring an additional 394 shares in the last quarter. Principal Financial Group Inc. lifted its position in shares of ANI Pharmaceuticals by 6.9% in the 3rd quarter. Principal Financial Group Inc. now owns 89,961 shares of the specialty pharmaceutical company's stock worth $5,367,000 after acquiring an additional 5,829 shares during the period. Finally, Summit Global Investments lifted its position in shares of ANI Pharmaceuticals by 154.2% in the 3rd quarter. Summit Global Investments now owns 19,704 shares of the specialty pharmaceutical company's stock worth $1,176,000 after acquiring an additional 11,952 shares during the period. 76.05% of the stock is owned by institutional investors.
About ANI Pharmaceuticals
(
Get Free Report)
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
See Also
Before you consider ANI Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.
While ANI Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
